COVID-19 trials registries data warehouse

 Return to trial list

Trial - CTRI/2022/03/041214


Column Value
Trial registration number CTRI/2022/03/041214
Full text link
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

First author
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Dr Nilesh Patel

Contact
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

nileshp@panexcell.com

Registration date
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2022-03-21

Recruitment status
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Not recruiting

Study design
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

RCT

Allocation
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Randomized

Design
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Parallel

Masking
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Blind label

Center
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

multi-center

Study aim
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Treatment

Inclusion criteria
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1. Patient with RT-PCR positive for nCOVID-19 within last 72 hours with Ct value > 17. <br/ >2. Male and female patients with age above 18 years and below 65 years of age. <br/ >3. Patient with ARVI score atleast 2 or more. <br/ >4. Patient willing to provide informed consent to participate into the trial. <br/ >5. Patient able to complied requirement of study and protocol. <br/ >6. Patient with SpO2 > 94 %, Respiratory rate < 24/min and temperature < 104 °F <br/ >

Exclusion criteria
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1. Known hypersensitivity or idiosyncratic reaction to Chlorine or any of related substance or ingredient of the formulation. <br/ >2. Patient having past history of respiratory disorder like COPD, Asthma etc. <br/ >3. Patient is on medication before tested nCOVID 19 positive for respiratory disease or disorder (other than viral infection). <br/ >4. Patient was on immunomodulatory drug. <br/ >5. Patient who has participated in other clinical study related to nCOVID 19. <br/ >6. Patients with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.. <br/ >7. Patients who are diagnosed and/or on treatment for venous thromboembolism, ischemic heart disease, myocardial infarction, congestive cardiac failure, unexplained vaginal bleeding with suspicion of serious underlying condition, history of breast or cervical cancer, malignant tumor. <br/ >8. Patient of Hypertension and/or Diabetes who was not on stable treatment in past 3 month. <br/ >9. Known history of Chronic Kidney disease. <br/ >10. Known history of Chronic Liver disease. <br/ >11. Reports of any history of malignancy. <br/ >12. Nursing mother or pregnant women. <br/ >

Number of arms
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

2

Funding
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Supreme Drugs Pvt Ltd

Inclusion age min
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

18

Inclusion age max
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

65

Countries
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

India

Type of patients
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Mild disease at enrollment

Severity scale
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

1: Mild disease at enrollment

Total sample size
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

184

primary outcome
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

At least decrease in Ordinal Scale by 1 pointTimepoint: Day 4; Day 6

Notes
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

| Declared number of arm (3.0) differs from found arms (4.0)

Phase
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

Phase 3

Arms
Last imported at : April 8, 2022, 3:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)

[{"arm_notes": "", "treatment_id": 2428, "treatment_name": "Chlorine inhalation", "treatment_type": "Respiratory agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]